AI and Machine Learning in Drug Discovery: Current Applications, Challenges, and Future Directions in Pharmaceutical Research

Neeraj Nikunj[1], Himanshu Chouhan[1] Pallavi Chand[1], Vikash Jhakhmola[1]
Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Premnagar, Dehradun, Uttarakhand, India, 248007

***Abstract*—The integration of Artificial Intelligence (AI) in drug discovery has revolutionized pharmaceutical research, significantly reducing the time and cost associated with developing new drugs. AI, particularly Machine Learning (ML) and Deep Learning (DL) techniques, has enabled computer-aided drug discovery by leveraging vast biomedical datasets, advanced computing power, and cloud storage. DL models, such as artificial neural networks (ANNs), have enhanced predictive accuracy in key drug discovery processes, including drug–target interactions (DTIs), drug–drug similarity interactions (DDIs), drug sensitivity analysis, and side-effect predictions. Furthermore, AI-driven methodologies are accelerating the development of drugs for complex conditions, particularly central nervous system (CNS) disorders, where challenges such as blood–brain barrier permeability and high attrition rates persist. AI-powered techniques, including de novo drug design, virtual screening, and drug repurposing, have shown promise in tackling neurological diseases like Alzheimer's, Parkinson's, and schizophrenia. Additionally, Explainable AI (XAI) is being incorporated to enhance transparency in drug discovery models, while digital twinning (DT) is emerging as a future research avenue. Open data sharing, model augmentation, and advancements in hybrid AI approaches will further strengthen AI's role in pharmaceutical innovation, offering more efficient, cost-effective, and successful drug discovery strategies.**

***Keywords*— Artificial Intelligence, Machine Learning, Deep Learning, Drug Discovery, Neural Networks, Drug–Target Interactions, Drug Repurposing, CNS Disorders, Explainable AI, Digital Twinning.**

I. INTRODUCTION

The course of research and development of drugs is comprised of drug-target recognition, target authentication, hit-to-lead fructification, lead refinement, preclinical molecule determination, and preclinical evaluation, as well as clinical testing. To advance a new prescription drug to market, the mean pretax spending is almost USD 2.6 billion, requiring roughly 10–15 years. However, considering the huge financial stakes, the predicted clinical approval realization frequency for novel small agents during the discovery and development of drugs is a meager 13%, with a rather steep possibility of ultimate non-fruition.

The advance of computer-enabled drug design technology has been hailed as the most resourceful method for altering this bleak scenario dependent upon prudent navigation in the development process. The methodology pertinent to drug discovery and the associated computer-enabled drug design approaches can be located in the treatise "Computer-Assisted Drug Design." The computational approaches assure a methodical appraisal of the molecular attributes (such as physicochemical properties, selectivity, side effects, bioactivity, and pharmacokinetic parameters) at the speculative level, in concert with engendering optimized molecules having agreeable attributes in silico.

Moreover, computational approaches with multi-objective refinement can be engaged to reduce the failure frequency of the preclinical lead molecules. In the vista of drug design, artificial intelligence (AI) invokes computer software programs that evaluate, learn, and reveal pharmaceutical-associated big data to unravel new medicine molecules, by assimilating the advances in machine learning (ML) in a highly unified and mechanized way. Deep learning (DL) models are advancing rapidly, and as the volume of drug-related data grows, innovative DL-based approaches are emerging at every stage of the drug development process (Kim et al., 2021). Major pharmaceutical companies are decisively shifting towards AI technologies, abandoning outdated and ineffective methods to maximize patient outcomes and their own profitability (Nag et al., 2022). While

DL has demonstrated impressive performance, the challenges it presents are significant, and there is a clear opportunity for researchers to create algorithms that enhance drug discovery. This paper delivers a comprehensive systematic literature review (SLR) that consolidates the latest DL technologies and applications in drug discovery.



Figure 1. Conceptual Interrelationships between Artificial Intelligence(AI), Machine Learning(ML),& Deep Learning(DL) for drug development.



Figure 2. A Summarized Notion of AI & ML Tools engaged in Drug Discovery & Development

1.1. Artificial Intelligence: Important Considerations

In recent years, there has been a significant increase in data digitalization within the pharmaceutical sector. This digital transformation has been driven by the necessity to collect, analyze, and utilize expertise to tackle complex clinical challenges. This has led to the application of AI, which has the capability to handle vast amounts of data with enhanced automation. AI employs a technology-driven strategy that involves various advanced tools and networks that mimic human intelligence. Importantly, it does not raise concerns about completely replacing human existence. AI makes use of software and systems that are designed to interpret data and are trained using input data to produce independent results aimed at achieving specific objectives. As highlighted in this review, its application has experienced steady growth within the pharmaceutical industry. The rapid

advancement of AI-driven automation is likely to significantly transform the societal work environment.

1.2. AI: Networks and Tools

AI encompasses a variety of methodological areas, including knowledge representation, problem-solving, and reasoning, and among these is itself a fundamental illustration of ML. ML employs algorithmic approaches that can identify patterns within a dataset, which can then be organized further. A key aspect of ML is deep learning (DL), which utilizes artificial neural networks (ANNs). These networks consist of a collection of interconnected, advanced computational units known as 'perceptrons,' which resemble neurons found in human neural tissue and mimic the transmission of electrical signals within the human central nervous system (CNS). ANNs are made up of multiple nodes, with each node receiving a unique input and ultimately transforming those inputs into outputs, either individually or collectively, through algorithms that solve problems.

There are various types of ANNs, such as multilayer perceptron (MLP) networks, recurrent neural networks (RNNs), and convolutional neural networks (CNNs), which can be trained through either supervised or unsupervised methods. MLP networks are useful for applications including pattern recognition, optimization, decision-making processes, and control systems.

RNNs feature a feedback loop, allowing them to store and memorize data, including components like Boltzmann machines and Hopfield networks. CNNs consist of a series of dynamic systems that utilize local connections, each governed by its specific topological structure, and are employed in tasks such as image and video processing, biological system simulation, managing intricate central neuronal functions, pattern recognition, and advanced signal processing.

More complex architectures include Kohonen networks, Radial Basis Function (RBF) networks, Learning Vector Quantization (LVQ) networks, counter-propagation networks (CPNs), and Adaptive Linear Neuron networks, also known as Adaptive Linear Elements (ADALINE). Numerous algorithms have been developed based on the connections that form the foundational framework of AI systems.

An example of this sophisticated tool utilizing AI methods is IBM's Watson supercomputer. This computing system was created to analyze a patient's clinical information in relation to an extensive database, ultimately leading to the identification of treatment options for cancer. Additionally, this system can be employed for the rapid detection of diseases. Its effectiveness was demonstrated by its ability to diagnose breast cancer in just 60 seconds.

II. FUTURE USES OF AI IN DRUG DEVELOPMENT

The design and creation of drugs is a critical research focus for pharmaceutical firms and chemists. For a molecule to act as a potential drug, it must be deemed "druggable." In the era following the genomic revolution, drug discovery has evolved to implement novel design principles for molecules or fresh strategies to bind, modulate, or degrade difficult biological targets for groundbreaking medicines.

Historically, the pharmaceutical sector has concentrated on the creation of small molecules that are orally bioavailable and have well-defined targets (druggable targets). Lipinski's Rule of Five (Ro5) emerged based on the physicochemical characteristics of Phase II drugs to predict poor absorption or permeation rates derived from factors like hydrogen-bond donors, acceptors, molecular weight, and calculated Log P values.

Although the pursuit of small molecule Ro5 compounds interacting with known "druggable" targets has yielded positive results, there is a growing need for innovative approaches to target new biological entities for transformative treatments. Consequently, the identification and validation of novel biological targets are now pivotal in the preliminary phases of drug discovery.

Beyond Ro5, various molecular modalities like small molecules acting through alternative mechanisms (for instance, protein–protein interaction or PPI modulators), bifunctional small molecules (such as protein-targeted chimeras or PROTACs), peptides/peptidomimetics, and oligonucleotides (ONs) are being investigated.

Research into carbohydrate-based drug discovery is emerging in the realm of medicinal chemistry. The discovery of bioactive carbohydrates has introduced a new avenue for drug development. Over 170 carbohydrate-based pharmaceuticals have successfully been approved as anticoagulants, antitumor agents, antidiabetic agents, antibiotics, antiviral agents, and vaccines. However, the majority

of carbohydrates exhibit low druggability, creating a need for novel methods and strategies to enhance their therapeutic efficacy.

Lipids play a crucial role in living organisms. They reserve energy, form cellular membranes, act as signaling molecules, and modify proteins. Numerous medications targeting lipid receptors and the enzymes that govern lipid metabolism and function have been developed for diverse illnesses. The pathways and proteins involved in lipid signaling provide extensive opportunities within drug discovery.

Incorporating AI and ML into these processes holds the potential to transform drug discovery by refining molecular interactions, decreasing rates of failure, and hastening development timelines.

2.1 Digitizing and Standardizing Synthesis Methods

Far-sighted plans are developing to harness AI to fully mechanize chemical synthesis with a minimum of manual operations. Already proven processes, such as the 'solid phase' strategy in which the growing polymer chain is attached to some highly insoluble matrix, have mechanized the syntheses of many classes of agents, such as peptides or oligonucleotides.

Nevertheless, there are specific protocols governing these as there is no standardized digital mechanization of computer monitoring of the chemical reactions, and no universal software is associated with computational governance of chemical operation systems. The "Chemputer platform" was newly advanced as a standard benchmark that integrated codified standard recipes, or chemical codes, for compound synthesis.

The scheme was executed with the "Chempiler program," which obtains codified methods from a scripting language called "Chemical Assembly (ChASM)." This language also regulates distinct low-level execution rules for the modules that make up the structure of the robotic system. ChASM draws upon a chemical descriptive language (XDL), which exclusively and methodically amasses the complete obligatory information for a synthesis operation.

The physical modules (e.g., the source flask and the target flask) and their network arrangement and portrayal are depicted as a directed graph by engaging an open-source markup language termed "GraphML." With GraphML, Chempiler is capable of governing robotic procedures in a manner that allows users to execute chemical syntheses without manual restructuring.

The first presents very convincing results of automatic synthesis of three different, distinct pharmaceutical patient molecules: diphenhydramine hydrochloride, rufinamide, and sildenafil, without any human involvement but with output and quality levels either equivalent or better than the manipulated ones. This is a gigantic leap on the whole mechanization of bench-scale chemistry, coupled with other improvements in replicability, security, and approachability to complex compounds.

Table 1. Enumeration of AI-Aided Computational Tools for Facilitating Drug Discovery

Tools	Feature(s)	Website(s)
AlphaFold	Protein 3D (tertiary) structure presage employing DNN	https://deepmind.com/blog/alphafold https://www.sciencemag.org/news/2018/12/google-s-deepmind-aces-protein-folding
Chemputer	An exhaustive regulated schema for documenting a chemical synthesis method	https://zenodo.org/record/1481731
Conv_qsar_fast	Foretells molecular attributes aided by CNN algorithm	https://github.com/connorcoley/conv_qsar_fast
Chemical VAE	Mechanized chemical crafting employing variational autoencoder (VAE)	https://github.com/aspuru-guzik-group/chemical_vae
DeepChem	A Python-aided AI technique for drug discovery predictions utilizing DL	https://github.com/deepchem/deepchem
DeepNeuralNet-QSAR	Foretells molecular activity engaging multilevel DNN	https://github.com/Merck/DeepNeuralNet-QSAR
DeepTox	Toxicity predictions of chemical agents utilizing a DL algorithm	www.bioinf.jku.at/research/DeepTox

DeltaVina	Presages small molecule interaction affinity with drug using RF and AutoDock	https://github.com/chengwang88/deltavina
Hit Dexter	ML schemes for predicting compounds sensitive to biochemical assays	http://hitdexter2.zbh.uni-hamburg.de
InnerOuterRNN	Foretells chemical, physical, and biological attributes using RNNs	https://github.com/Chemoinformatics/InnerOuterRNN
JunctionTree VAE	De novo molecule origination using junction tree variational autoencoder (VAE)	https://github.com/wengong-jin/icml18-jtnn
Neural Graph Fingerprints	Attribute augury of novel molecules employing CNN algorithms	https://github.com/HIPS/neural-fingerprint
NNScore	Foretells affinity of protein–ligand binding using neural network scoring	http://rocce-vm0.ucsd.edu/data/sw/hosted/nnscore/ http://www.nbcr.net/software/nnscore
ODDT	An exhaustive toolkit for chemoinformatics and molecular modelling	https://github.com/oddt/oddt
ORGANIC	A molecular generation tool to originate molecules with favorable attributes	https://github.com/aspuru-guzik-group/ORGANIC
PotentialNet	Foretells ligand-binding affinity using graph CNN	https://pubs.acs.org/doi/full/10.1021/acscentsci.8b00507
PPB2	Poly-pharmacology prediction using nearest neighbour and ML schemes	http://ppb2.gdb.tools/
QML	A Python toolkit for quantum ML	https://www.qmlcode.org https://github.com/qmlcode/qm
REINVENT	De novo design of molecules using RNN and RL	https://github.com/MarcusOlivecrona/REINVENT
SCScore	A scoring scheme to determine the synthesis complexity of a compound	https://github.com/connorcoley/scscore
SIEVE-Score	An upgraded technique for structure-aided virtual screening	https://github.com/sekijima-lab/SIEVE-Score

III. TECHNIQUES OF DEEP LEARNING (DL)

The uses of machine learning (ML) in research applications have ranged from spam detection to video recommendations, image classification, and multimedia information retrieval. Deep learning (DL) is one of the most frequently employed techniques in ML applications. New strivings into DL research have come due to the ever elusive acquisition of data and the phenomenal advancement of hardware technologies. Deep learning is an extra mile ahead of the traditional neural networks that form the architectural basis of the technique, by using transformations and graph technology in constructing multi-layer-feature learning models. These were thousands of miles away from the original world-from out-of-the-box thinking of much thinking much differently.

3.1 Classic Neural Networks

The most often applied representation for neural networks is multi-layer perceptrons. This translates to encoding the algorithm into simple two-digit data inputs going into it. The model allows for input of both linear and nonlinear functions. While the linear function takes the shape of a single line maintained at a constant multiplier that changes its inputs, the nonlinear functions include the Sigmoid Curve, Hyperbolic Tangent, and Rectified Linear Unit. Therefore, this model is the most suited for categorization and regression problems involving real-valued data and a flexible model of any kind.

Convolutional Neural networks (CNNs) are a commonly used neural network to process both images and non-images. CNNs can go through four phases:

Input Layer: The raw sensory mechanism processes data, such as that corresponding to an image, as a two-dimensional array of neurons.
Convolutional Layers: These layers analyze images based on their inputs using a single-dimensional output layer of neurons.
Sampling Layer: This is the layer restricting the number of neurons that can participate in the subsequent levels of the network.
Fully Connected Layers: These layers link the sampling and the output layers, thus enabling CNNs to extract meaningful vision information, layer by layer.

When the input data is integrated into the convolutional model, CNNs are processed in the following four stages:
Convolution: Generates feature maps on the basis of supplied data.
Max-Pooling: Facilitates detecting an image by modification of input data.
Flattening: Adaptation of data into configurations for further processing by CNN.
Full Connection: Also called "hidden layer," it establishes the loss function for a model.
CNN is used in image recognition, image analysis, image segmentation, video analysis, and natural language processing tasks.

3.2 Recurrent Neural Networks (RNNs)
The idea of RNNs emerged to predict sequences. These networks use streams of data, which could have different lengths, as inputs. For the latest forecast, the knowledge gained in the previous state serves as input, thereby facilitating some short-term memory.

LSTMs, a type of RNN, are best known for their extra flexibility in many applications. The strength of LSTMs in time-sequenced data predictions hinges on their three gates, namely Input, Output, and Forget, which control the flow of information. Generally, Gated RNNs serve well in the prediction of temporal sequences and memory-based data analysis.
Activities include, but are not limited to, image classification, sentiment analysis, video classification, and language translation.

3.3 Generative Adversarial Networks (GANs)
GANs consist of two neural networks, namely, a Generator and a Discriminator. The Discriminator is used to distinguish between real and fake data, while the Generator is tasked with creating synthetic data.

These networks work against each other: the Discriminator keeps getting better at telling real and fake data apart, while the Generator tries harder and harder to make the data it generates look real. The Generator network is especially relevant for image and text generation, image enhancement, and even drug development.

3.4 Self-Organizing Maps (SOMs)
Self-Organizing Maps apply with minimal supervision and use the data to diminish the number of random variables within a system. Each synapse is linked both to an input node and to an output node arranged in a two-dimensional model.
In the processing phase, there occurs competition between the data points and their representation in the model, whereupon the winners or the closest nodes (Best Matching Units) get adjusted. The weight of the BMUs is dependent on their distance, which denotes where they stand in the network in relation to other BMUs. This is an effective method for analyzing datasets for which there is no preset Y-axis value, or for work in an exploration.

3.5 Boltzmann Machines
Boltzmann Machines are a type of neural network model that is different, wherein nodes are interconnected in a loop without orientation. This deep learning technique works mainly in generating model parameters because of its stochasticity, which separates it from deterministic network models.
Boltzmann Machines find applications for monitoring the behavior of systems, constructing binary recommendation engines, and analyzing particular datasets.
The architecture of the Boltzmann Machine consists of two layers:
Visible/Input Layer: Receives the raw data.
Hidden Layer: Processes the input data with neuron-like nodes.
The connections between the nodes in the different layers are at different levels, but there is no interconnectivity within a layer. The lack of direct interconnectivity across nodes in the same layer is one of the drawbacks of Boltzmann Machines.

Data upon introduction is transferred to a graph setting for the network to process, learn patterns and relationships, and decide accurately. With these features, the Boltzmann M

REFERENCE

[1] DiMasi, J.A.; Grabowski, H.G.; Hansen, R.W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ. 2016, 47, 20–33. [CrossRef] [PubMed]

[2] Turner, J.R. New Drug Development; Springer: New York, NY, USA, 2010.

[3] Hassan Baig,M.; Ahmad, K.; Roy, S.;Mohammad Ashraf, J.; Adil,M.; Haris Siddiqui,M.; Khan, S.; Amjad Kamal,M.; Provazník, I.; Choi, I. Computer aided drug design: Success and limitations. Curr. Pharm. Des. 2015, 22, 572–581. [CrossRef] [PubMed]

[4] Mason, J.S. Introduction to the volume and overview of computer assisted drug design in the drug discovery process. In Comprehensive Medicinal Chemistry II; Taylor, J.B., Triggle, D.J., Eds.; Elsevier: Amsterdam, The Netherlands, 2007; pp. 1–11.

[5] Swaminathan, K.; Meller, J. Artificial Intelligence Approaches for Rational Drug Design and Discovery. Curr. Pharm. Des. 2007, 13, 1497–1508. [CrossRef]

[6] Lavecchia, A.; Di Giovanni, C. Virtual screening strategies in drug discovery: A critical review. Curr. Med. Chem. 2013, 20, 2839–2860. [CrossRef] [PubMed]

[7] Melville, J.L.; Burke, E.K.; Hirst, J.D. Machine Learning in Virtual Screening. Comb. Chem. High Throughput Screen. 2009, 12, 332–343. [CrossRef]

[8] Ma, J.; Sheridan, R.P.; Liaw, A.; Dahl, G.E.; Svetnik, V. Deep neural nets as a method for quantitative structure-activity relationships. J. Chem. Inf. Model. 2015, 55, 263–274. [CrossRef]

[9] Angermueller, C.; Pärnamaa, T.; Parts, L.; Stegle, O. Deep learning for computational biology.Mol. Syst. Biol. 2016, 12, 878. [CrossRef]

[10] LeCun, Y.; Bengio, Y.; Hinton, G. Deep learning. Nature 2015, 521, 436–444. [CrossRef]

[11] Schmidhuber, J. Deep Learning in Neural Networks: An Overview. Neural Netw. 2015, 61, 85–117. [CrossRef]

[12] Goodfellow, I.; Bengio, Y.; Courville, A. Deep Learning; The MIT Press: Cambridge, UK, 2016.

[13] Ramesh, A.; Kambhampati, C.; Monson, J.R.; Drew, P.J. Artificial intelligence in medicine. Ann. R. Coll. Surg. Engl. 2004, 86, 334–338. [CrossRef]

[14] Miles, J.; Walker, A. The potential application of artificial intelligence in transport. IEEE Proc. Intell. Transp. Syst. 2006, 153, 183–198. [CrossRef]

[15] Yang, Y.; Siau, K. A Qualitative Research on Marketing and Sales in the Artificial Intelligence Age. In Proceedings of the Midwest United States Association for Information Systems(MWAIS), St. Louis, MO, USA, 17–18 May 2018.

[16] Wirtz, B.W.; Weyerer, J.C.; Geyer, C. Artificial Intelligence and the Public Sector—Applications and Challenges. Int. J. Public Adm. 2018, 42, 596–615. [CrossRef]

[17] Smith, R.G.; Farquhar, A. The road ahead for knowledge management: An AI perspective. AI Mag. 2000, 21, 17.

[18] Lamberti, M.J.; Wilkinson, M.; Donzanti, B.A.; Wohlhieter, G.E.; Parikh, S.; Wilkins, R.G.; Getz, K. A Study on the Application and Use of Artificial Intelligence to Support Drug Development. Clin. Ther. 2019, 41, 1414–1426. [CrossRef]

[19] Beneke, F.; Mackenrodt, M.-O. Artificial intelligence and collusion. IIC Int. Rev. Intellect. Prop. Compet. Law 2019, 50, 109–134. [CrossRef]

[20] Steels, L.; Brooks, R. The Artificial Life Route to Artificial Intelligence: Building Embodied, Situated Agents; Routledge: London, UK, 2018.

[21] Bielecki, A.; Bielecki, A. Foundations of artificial neural networks. In Models of Neurons and Perceptrons: Selected Problems and Challenges; Janusz, K., Ed.; Springer International Publishing: Cham, Switzerland, 2019; pp. 15–28.

[22] Kalyane, D.; Sanap, G.; Paul, D.; Shenoy, S.; Anup, N.; Polaka, S.; Tambe, V.; Tekade, R.K. Artificial intelligence in the pharmaceutical sector: Current scene and future prospect. In The Future of Pharmaceutical Product Development and Research; Academic Press: Cambridge, MA, USA, 2020; pp. 73–107. [CrossRef]

[23] da Silva, I.N.; Spatti, D.H.; Flauzino, R.A.; Liboni, L.H.B.; Alves, S.F.D.R. Artificial Neural Network Architectures and Training Processes. In Artificial Neural Networks; Springer: Cham, Switzerland, 2016; pp. 21–28. [CrossRef]

[24] Medsker, L.; Jain, L.C. Recurrent Neural Networks: Design and Applications; CRC Press: Boca Raton, FL, USA, 1999.

[25] Hanggi, M.; Moschytz, G.S. Cellular Neural Networks: Analysis, Design and Optimization; Springer Science & Business Media: Berlin, Germany, 2000.

[26] Rouse, M. IBM Watson Supercomputer. 2017. Available online: https://searchenterpriseai.techtarget.com/definition/IBMWatson- supercomputer (accessed on 13 October 2020).

[27] Vyas, M.; Thakur, S.; Riyaz, B.; Bansal, K.K.; Tomar, B.; Mishra, V. Artificial intelligence: The beginning of a new era in pharmacy profession. Asian J. Pharm. 2018, 12, 72–76.

[28] Spencer, M.; Eickholt, J.; Cheng, J. A Deep Learning Network Approach to ab initio Protein Secondary Structure Prediction. IEEE/ACM Trans. Comput. Biol. Bioinform. 2014, 12, 103–112. [CrossRef]

[29] Li, H.; Hou, J.; Adhikari, B.; Lyu, Q.; Cheng, J. Deep learning methods for protein torsion angle prediction. BMC Bioinform. 2017, 18, 417. [CrossRef]

[30] Wang, S.; Sun, S.; Li, Z.; Zhang, R.; Xu, J. Accurate De Novo Prediction of Protein Contact Map by Ultra-Deep Learning Model. PLoS Comput. Biol. 2017, 13, e1005324. [CrossRef]

[31] Schaarschmidt, J.; Monastyrskyy, B.; Kryshtafovych, A.; Bonvin, A.M. Assessment of contact predictions in CASP12: Co-evolution and deep learning coming of age. Proteins Struct. Funct. Bioinform. 2017, 86, 51–66. [CrossRef]

[32] Falchi, F.; Caporuscio, F.; Recanatini, M. Structure-based design of small-molecule protein–protein interaction modulators: The story so far. Futur. Med. Chem. 2014, 6, 343–357. [CrossRef] [PubMed]

[33] Scott, D.E.; Bayly, A.R.; Abell, C.; Skidmore, J. Small molecules, big targets: Drug discovery faces the protein-protein interaction challenge. Nat. Rev. Drug Discov. 2016, 15, 533–550. [CrossRef] [PubMed]

[34] Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.; Tsafou, K.P.; et al. STRING v10: Protein-Protein Interaction Networks, Integrated Over the Tree of Life. Nucleic Acids Res. 2015, 43, D447–D452. [CrossRef] [PubMed]

[35] Cukuroglu, E.; Engin, H.B.; Gursoy, A.; Keskin, O. Hot spots in protein–protein interfaces: Towards drug discovery. Prog. Biophys. Mol. Biol. 2014, 116, 165–173. [CrossRef] [PubMed]

[36] Higueruelo, A.P.; Jubb, H.; Blundell, T.L. Protein–protein interactions as druggable targets: Recent technological advances. Curr. Opin. Pharmacol. 2013, 13, 791–796. [CrossRef]

[37] Senior, A.W.; Evans, R.; Jumper, J.; Kirkpatrick, J.; Sifre, L.; Green, T.; Qin, C.; Žídek, A.; Nelson, A.W.R.; Bridgland, A.; et al. Improved protein structure prediction using potentials from deep learning. Nature 2020, 577, 706–710. [CrossRef]

[38] Zhu,H. Big Data and Artificial IntelligenceModeling for Drug Discovery. Annu. Rev. Pharmacol. Toxicol. 2020, 60, 573–589. [CrossRef]

[39] Ghasemi, F.; Mehridehnavi, A.; Fassihi, A.; Pérez-Sánchez, H. Deep neural network in biological activity prediction using deep belief network. Appl. Soft Comput. 2018, 62, 251–258. [CrossRef]

[40] Mayr, A.; Klambauer, G.; Unterthiner, T.; Hochreiter, S. DeepTox: Toxicity Prediction using Deep Learning. Front. Environ. Sci. 2016, 3, 80. [CrossRef]

[41] Stork, C.; Chen, Y.; Šícho, M.; Kirchmair, J. Hit Dexter 2.0: Machine-Learning Models for the Prediction of Frequent Hitters. J. Chem. Inf. Model. 2019, 59, 1030–1043. [CrossRef] [PubMed]

[42] Urban, G.; Subrahmanya, N.; Baldi, P. Inner and Outer Recursive Neural Networks for Chemoinformatics Applications. J. Chem. Inf. Model. 2018, 58, 207–211. [CrossRef] [PubMed]

[43] Jin, W.; Barzilay, R.; Jaakkola, T. Junction tree variational autoencoder for molecular graph generation. In Proceedings of the 35th International Conference on Machine Learning, PMLR, Stockholmsmässan, Stockholm, Sweden, 10–15 July 2018; pp. 2323–2332.

[44] Duvenaud, D.K.; Maclaurin, D.; Iparraguirre, J.; Gomez-Bombarelli, R.; Hirzel, T.; Aspuru-Guzik, A.; Adams, R.P. Convolutional networks on graphs for learning molecular fingerprints. In Advances in Neural Information Processing Systems; Cortes, C., Lawrence, N., Lee, D., Sugiyama, M., Garnett, R., Eds.; Curran Associates, Inc.: Red Hook, NY, USA, 2015; pp. 1–9.

[45] Durrant, J.D.; McCammon, J.A. NNScore 2.0: A Neural-Network Receptor–Ligand Scoring Function. J. Chem. Inf. Model. 2011, 51, 2897–2903. [CrossRef] [PubMed]

[46] Wójcikowski, M.; Zielenkiewicz, P.; Siedlecki, P. Open Drug Discovery Toolkit (ODDT): A new open-source player in the drug discovery field. J. Cheminform. 2015, 7, 26. [CrossRef] [PubMed]

[47] Sanchez-Lengeling, B.; Outeiral, C.; Guimaraes, G.L.; Aspuru-Guzik, A. Optimizing distributions over molecular space. An objective-reinforced generative adversarial network for inverse-design chemistry (ORGANIC). ChemRxiv 2017, 1–18.

[48] Feinberg, E.N.; Sur, D.; Wu, Z.; Husic, B.E.; Mai, H.; Li, Y.; Sun, S.; Yang, J.; Ramsundar, B.; Pande, V.S. PotentialNet for molecular property prediction. ACS Cent. Sci. 2018, 4, 1520–1530. [CrossRef]

[49] Awale, M.; Reymond, J.-L. Polypharmacology browser PPB2: Target prediction combining nearest neighbors with machine learning. J. Chem. Inf. Model. 2019, 59, 10–17. [CrossRef]

[50] Cho, A. No room for error. Science 2020, 369, 130–133. [CrossRef]

[51] Blaschke, T.; Arús-Pous, J.; Chen, H.; Margreitter, C.; Tyrchan, C.; Engkvist, O.; Papadopoulos, K.; Patronov, A. REINVENT 2.0: An AI Tool for De Novo Drug Design. J. Chem. Inf. Model. 2020, 60, 5918–5922. [CrossRef]

[52] Coley, C.W.; Rogers, L.; Green, W.H.; Jensen, K.F. SCScore: Synthetic Complexity Learned from a Reaction Corpus. J. Chem. Inf. Model. 2018, 58, 252–261. [CrossRef]

[53] Yasuo, N.; Sekijima, M. Improved Method of Structure-Based Virtual Screening via Interaction-Energy-Based Learning. J. Chem. Inf. Model. 2019, 59, 1050–1061. [CrossRef]

[54] Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT et al (2000) Gene ontology: tool for the unification of biology. Nat Genet 25:25–29

[55] Attwood MM, Fabbro D, Sokolov AV et al (2021) Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov 20(11):839–861

[56] Avila C, Alquicira-Hernandez J, Powell JE et al (2020) Benchmarking of cell type deconvolution pipelines for transcriptomics data. Nat Commun 11(1):5650

[57] Azad AKM, Dinarvand M, Nematollahi A, Swift J, Lutze-Mann L, Vafaee F (2021) A comprehensive integrated drug similarity resource for in-silico drug repositioning and beyond. Brief Bioinform 22(3):bbaa126. https://doi.org/10.1093/bib/bbaa126

[58] Badr S, Sugiyama H (2020) A PSE perspective for the efficient production of monoclonal antibodies: integration of process, cell, and product design aspects. Curr Opin Chem Eng 27:121–128

[59] Bao J, Guo D, Li J, Zhang J (2018) The modelling and operations for the digital twin in the context of manufacturing. Enterp Inf Syst 13:534–556

[60] Baptista D, Ferreira PG, Rocha M (2021) Deep learning for drug response prediction in cancer. Briefings Bioinform 22:360–379

[61] Barenji RV, Akdag Y, Yet B, Oner L (2019) Cyber-physical-based PAT (CPbPAT) framework for Pharma 4.0. Int J Pharm 567:118445

[62] Baumann P, Hubbuch J (2017) Downstream process development strategies for effective bioprocesses: Trends, progress, and combinatorial approaches. Eng Life Sci 17:1142–1158

[63] Beck BR, Shin B, Choi Y, Park S, Kang K (2020) Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug–target interaction deep learning model. Comput Struct Biotechnol J 18:784–790

[64] Bedi P, Sharma C, Vashisth P, Goel D, Dhanda M (2015) Handling cold start problem in Recommender Systems by using Interaction Based Social Proximity factor. In: Proceeding of the 2015 international conference on advances in computing, communications and informatics, Kerala, India, 10–13 August 2015; pp 1987–1993

[65] Benedek R, Stephen B, Andriy N, Michael U, Sebastian N, Eliseo P (2021) A unified view of relational deep learning for drug pair scoring. coRR V. https://arxiv.org/abs/2111.02916

[66] Betsabeh T, Mansoor ZJ (2021) Using drug–drug and protein-protein similarities as feature vector for drug–target binding prediction. Chemom Intell Lab Syst 217:104405. https://doi.org/10.1016/j.chemolab.2021.104405

[67] Bleakley K, Yamanishi Y (2009) Supervised prediction of drug–target interactions using bipartite local models. Bioinformatics 25:2397–2403

[68] Bolukbasi T (2016) Man is to computer programmer as woman is to homemaker? debiasing word embeddings. Advances in neural information processing systems, 2016; 29. In Identifying gender and sexuality of data subjects. https://cis.pubpub.org/pub/debiasing-word-embeddings-2016

[69] Bongini P, Pancino N, Dimitri GM, Bianchini M, Scarselli F, Lio P (2022) Modular multi-source prediction of drug side-effects with DruGNN. http://arxiv.org/abs/2202.08147